Susquehanna upgrades Metabasis Therapeutics, Inc. (Nasdaq: MBRX) to Positive with a $5 price target followign deal with Roche for HepDirect ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE